Our results suggest that inhibition of TOPK could be beneficial for at least two groups of CRC patients together representing 30–40% of all cases, namely, those with a KRAS or BRAF mutation and those with metastatic disease supported by several factors. The gene discussed is KRAS; the disease is metastatic neoplasm.